The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Ono's antisense therapy is to begin its first pivotal trial.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
